What the tirzepatide data actually tells us

SURMOUNT-1: the foundational weight-loss results

The trial that anchors almost every conversation about tirzepatide is SURMOUNT-1, published in the New England Journal of Medicine. It recruited 2,539 adults with a BMI of 30 or above (or 27 or above with at least one weight-related condition) who did not have type 2 diabetes. Participants received weekly injections of tirzepatide at 5mg, 10mg or 15mg, or placebo, alongside a reduced-calorie diet and increased physical activity, for 72 weeks.

At the 15mg dose, average weight reduction was around 20–21% of starting body weight. The 10mg arm, which you can read about in more detail on our tirzepatide 10 page, produced around 19%, and even the 5mg arm showed approximately 15% average loss. Placebo participants lost around 3%. These aren't cherry-picked best-case figures; they are the trial's primary endpoint results, cited directly by NICE when it made its recommendation.

A question our prescribers hear most weeks is whether those numbers apply to everyone. The honest answer is that they are averages from a carefully selected trial population. Individual responses vary (some people lose more, some less) and the data does not predict any single person's outcome. What the evidence does establish clearly is the scale of effect possible with this mechanism, something that simply was not achievable with older medicines at population level.

SURMOUNT-5: tirzepatide versus semaglutide head-to-head

Until 2025, comparisons between tirzepatide and semaglutide 2.4mg (Wegovy) were indirect — drawn from separate trials with different populations and designs. SURMOUNT-5 changed that. The open-label trial enrolled 751 adults with obesity but without diabetes and ran for 72 weeks, comparing tirzepatide directly against semaglutide 2.4mg. Tirzepatide produced greater average weight reduction, a result that NICE's committee noted when updating TA1026 in September 2025.

The margin narrowed with the approval of the higher 7.2mg semaglutide dose, and the clinical picture continues to evolve. For anyone considering which medicine may be appropriate, that is precisely the kind of nuance a prescriber works through, the aggregate data informs, but the individual consultation decides. You can read more about how the two medicines compare on our Mounjaro or tirzepatide page, which sets out the licensed differences alongside the evidence.

One point the data makes consistently: both medicines work better alongside structured diet and activity changes. The trial populations all had lifestyle support. That context is part of what the numbers reflect.

What the NICE recommendation means for the data's real-world application

NICE TA1026 translates the SURMOUNT evidence into NHS commissioning thresholds. The recommendation is for adults with a BMI of 35 or above and at least one weight-related comorbidity, conditions such as high blood pressure, type 2 diabetes, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease. For people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, those thresholds are set 2.5 kg/m² lower under UK guidance.

NICE also specifies that treatment should be reviewed at six months: if less than 5% of body weight has been lost at the highest tolerated dose, continuing is reconsidered. That threshold comes directly from the trial data's responder analyses, which showed that early response tends to predict longer-term benefit.

The private licensed threshold is different and somewhat broader: adults with a BMI of 30 or above, or 27 or above with at least one qualifying weight-related condition, may be considered. You can check how eligibility works in practice on the tirzepatide overview page, or explore the full range of weight-loss treatment options we prescribe. For cost context, our tirzepatide pricing page sets out what a private prescription typically involves. The NHS rollout, meanwhile, is phased by BMI and comorbidity count, detailed on our Mounjaro page.

Safety signals in the data

The trial data also informs the safety profile. The most commonly reported side effects across the SURMOUNT programme were gastrointestinal: nausea, diarrhoea, vomiting, constipation and indigestion. These were most pronounced after starting treatment or following a dose increase, and in most participants they were transient, settling within days to a couple of weeks. Injection-site reactions, fatigue, headache and dizziness were also recorded.

The NHS medicines page for tirzepatide summarises the side-effect profile clearly and is the best starting point for patients wanting a plain-English account. More serious but less common signals (including pancreatitis) are flagged in the prescribing information and in MHRA communications; any severe, persistent stomach pain that spreads to the back warrants urgent medical attention, not a wait-and-see approach.

Tirzepatide carries a Black Triangle (▼) designation, meaning it is subject to additional post-market monitoring. That isn't unusual for recently licensed medicines; it means any new safety findings are collected systematically. Patients can report suspected side effects through the MHRA's Yellow Card scheme. If you want to understand whether this treatment might suit you, and are curious about how tirzepatide 30 fits into the dosing journey, the right next step is speaking to a prescriber rather than interpreting the population data alone, check your eligibility by starting a free consultation.